Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Anthony, Mato"'
Autor:
Anthony Mato, Boxiong Tang, Soraya Azmi, Keri Yang, Yi Han, Xiaowei Zhang, Lindsey Roeker, Nicola Wallis, Jennifer C. Stern, Eric Hedrick, Jane Huang, Jeff P. Sharman
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 135-144 (2023)
Abstract Ibrutinib, a Bruton's tyrosine kinase inhibitor, is often used as first‐line (1L) treatment of chronic lymphocytic leukaemia (CLL); however, it is associated with an increased risk for cardiovascular adverse events (CVAEs). This real‐wor
Externí odkaz:
https://doaj.org/article/6e2bc983c365456688227cc361fb4cc9
Autor:
Jeff P. Sharman, Kim Cocks, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Kristen Sullivan, Mecide M. Gharibo, E. Dawn Flick, Andrew Trigg, Anthony Mato
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 188-198 (2020)
Abstract Health‐related quality of life (HRQoL) in patients with chronic lymphocytic leukemia (CLL) is important in guiding treatment decisions. However, the impact of CLL treatment initiation on HRQoL is unclear. We assessed HRQoL using the FACT
Externí odkaz:
https://doaj.org/article/34c06b8e749f4507ab23a49de144c417
Autor:
Kseniya Petrova-Drus, Mustafa Syed, Wayne Yu, Kasey Hutt, Alyssa M. Zlotnicki, Ying Huang, Monika Kamalska-Cyganik, Lidia Maciag, Meiyi Wang, Yuanyuan G. Ma, Caleb Ho, Christine Moung, Jinjuan Yao, Khedoudja Nafa, Jeeyeon Baik, Chad M. Vanderbilt, Jamal K. Benhamida, Ying Liu, Menglei Zhu, Benjamin Durham, Mark D. Ewalt, Paulo Salazar, Ivelise Rijo, Tessara Baldi, Anthony Mato, Lindsey E. Roeker, Mikhail Roshal, Ahmet Dogan, Maria E. Arcila
Publikováno v:
The Journal of Molecular Diagnostics. 25:352-366
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8f0c085798dbe1ee556056ce9fcb028
https://doi.org/10.1016/j.jmoldx.2023.02.005
https://doi.org/10.1016/j.jmoldx.2023.02.005
Autor:
Toby A. Eyre, Lisa M. Hess, Tomoko Sugihara, Dan He, Manoj Khanal, John M. Pagel, Richard A. Walgren, Paolo B. Abada, Heiko Konig, Lindsey E. Roeker, Anthony Mato
Publikováno v:
Leukemia & Lymphoma. :1-12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db91feb77ecc421e890e7a6be41232ac
https://doi.org/10.1080/10428194.2023.2190436
https://doi.org/10.1080/10428194.2023.2190436
Autor:
Deborah M. Stephens, Ken Boucher, Elizabeth Kander, Sameer A. Parikh, Erin M. Parry, Mazyar Shadman, John M. Pagel, Jennifer Cooperrider, Joanna Rhodes, Anthony Mato, Allison Winter, Brian Hill, Sameh Gaballa, Alexey Danilov, Tycel Phillips, Danielle M. Brander, Sonali M. Smith, Matthew Davids, Kerry Rogers, Martha J. Glenn, John C. Byrd
Publikováno v:
Haematologica, Vol 106, Iss 11 (2020)
Chronic lymphocytic leukemia (CLL) patients who develop Hodgkin lymphoma (HL) have limited survival. No current therapeutic standard of care exists. We conducted a multi-center retrospective study of patients with Hodgkin transformation (HT) of CLL.
Externí odkaz:
https://doaj.org/article/0260f2bf0b3e47f7bd3285461f73f519
Autor:
Davide Rossi, Mazyar Shadman, Adalgisa Condoluci, Jennifer R. Brown, John C. Byrd, Gianluca Gaidano, Michael Hallek, Peter Hillmen, Anthony Mato, Emili Montserrat, Paolo Ghia
Publikováno v:
HemaSphere, Vol 4, Iss 4, p e432 (2020)
Abstract. Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). These can be exacerbated by anti-leukemic treatments. In addition, the typical patients with CLL already have fragilities and backg
Externí odkaz:
https://doaj.org/article/625f1593a816404b8d6b26698be15c38
Autor:
Inhye E. Ahn, Charles M. Farber, Matthew S. Davids, David L. Grinblatt, Neil E. Kay, Nicole Lamanna, Anthony Mato, Chadi Nabhan, Pavel Kiselev, Arlene S. Swern, E. Dawn Flick, Kristen Sullivan, Jeff P. Sharman, Christopher R. Flowers
Publikováno v:
Blood Advances, Vol 1, Iss 25, Pp 2433-2443 (2017)
Abstract: Chemoimmunotherapy for chronic lymphocytic leukemia (CLL) promotes clonal evolution of aggressive clones, which in some patients may lead to early progression of disease (POD). We studied the prognostic value of early POD in a cohort of pat
Externí odkaz:
https://doaj.org/article/f151c5319e37462ba900987b62bc8361
Autor:
Lindsey Elizabeth Roeker, Maral DerSarkissian, Kellie Ryan, Yan Chen, Mei Sheng Duh, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, Anthony Mato
Publikováno v:
Blood Advances.
Novel agents, including Bruton tyrosine kinase inhibitors (BTKis), have become the standard of care for patients with chronic lymphocytic leukemia (CLL). We conducted a real-world retrospective analysis of CLL patients treated with acalabrutinib vs i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::496409d06453b1264f0f320ac7092cf9
https://doi.org/10.1182/bloodadvances.2023009739
https://doi.org/10.1182/bloodadvances.2023009739
Autor:
William G. Wierda, Jennifer Brown, Jeremy S. Abramson, Farrukh Awan, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Asher A. Chanan-Khan, Steve E. Coutre, Randall S. Davis, Herbert Eradat, Christopher D. Fletcher, Sameh Gaballa, Armin Ghobadi, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Brian Hill, Paul Kaesberg, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Anthony Mato, Claudio Mosse, Stephen Schuster, Tanya Siddiqi, Deborah M. Stephens, Chaitra Ujjani, Nina Wagner-Johnston, Jennifer A. Woyach, J. Christine Ye, Mary A. Dwyer, Hema Sundar
Publikováno v:
Journal of the National Comprehensive Cancer Network. 20:622-634
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30c8aded1262cbc6543928cc2785abf8
https://doi.org/10.6004/jnccn.2022.0031
https://doi.org/10.6004/jnccn.2022.0031
Autor:
James Collins, Sarah E. Stump, Hillary Heiling, Michele Muir, Allison Deal, Darrian Proco, Catharine Nguyen, Monica Cozad, Anthony Mato, Catherine C. Coombs, Benyam Muluneh
Publikováno v:
Leukemia & Lymphoma. 63:1823-1830
Ibrutinib is an oral Bruton's tyrosine kinase inhibitor approved for treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Clinical trial data suggest that strict adherence is directly related to clinical outcomes. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5c7ca634e245df0c091c0d2b662c17
https://doi.org/10.1080/10428194.2022.2045597
https://doi.org/10.1080/10428194.2022.2045597